Skip to main content
. 2015 Dec 1;113(12):1651–1657. doi: 10.1038/bjc.2015.405

Table 3a. DFS and OS outcomes for all patients.

      5-Year rate
  Hazard ratio (95% CI)a P-valueb Abbreviated trastuzumab N=115 Conventional trastuzumab N=112
DFS 1.31 (0.79–2.12) 0.31 76% 73%
OS 1.37 (0.74–2.54) 0.32 89% 83%

Abbreviations: CI=confidence interval; DFS=disease-free survival; OS=overall survival.

a

Hazard ratio for conventional trastuzumab vs abbreviated trastuzumab.

b

Based on log-rank test.